ALK and non-small cell lung carcinoma: Recent research regarding targeted therapy such as epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) and anaplastic lymphoma kinase inhibitors (ALK‐TKIs) has revealed significant improvements in overall survival rates of NSCLC patients harboring EGFR mutation or ALK rearrangement.